591 related articles for article (PubMed ID: 30456520)
1. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
2. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
Pollock RF; Muduma G
J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
[No Abstract] [Full Text] [Related]
3. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.
Pollock RF; Muduma G
Expert Opin Drug Deliv; 2017 Dec; 14(12):1439-1446. PubMed ID: 29032713
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
[TBL] [Abstract][Full Text] [Related]
5. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
Pollock RF; Muduma G
Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
[TBL] [Abstract][Full Text] [Related]
6. Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland.
Loughnane F; Muduma G; Pollock RF
Adv Ther; 2020 Mar; 37(3):1218-1232. PubMed ID: 32030608
[TBL] [Abstract][Full Text] [Related]
7. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000.
Pollock RF; Muduma G
Clinicoecon Outcomes Res; 2017; 9():475-483. PubMed ID: 28848355
[TBL] [Abstract][Full Text] [Related]
8. Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland.
Aksan A; Schoepfer A; Juillerat P; Vavricka S; Bettencourt M; Ramirez de Arellano A; Gavata S; Morin N; Valentine WJ; Hunt B
Adv Ther; 2021 Jan; 38(1):660-677. PubMed ID: 33216324
[TBL] [Abstract][Full Text] [Related]
9. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
[TBL] [Abstract][Full Text] [Related]
11. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
Bager P; Dahlerup JF
J Crohns Colitis; 2010 Oct; 4(4):427-30. PubMed ID: 21122539
[TBL] [Abstract][Full Text] [Related]
12. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
[TBL] [Abstract][Full Text] [Related]
13. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
[TBL] [Abstract][Full Text] [Related]
14. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
Cococcioni L; Pensabene L; El-Khouly S; Chadokufa S; McCartney S; Saliakellis E; Kiparissi F; Borrelli O
Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
[TBL] [Abstract][Full Text] [Related]
15. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy.
Rognoni C; Ortalda V; Biasi C; Gambaro G
Adv Ther; 2019 Nov; 36(11):3253-3264. PubMed ID: 31489572
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
Reinisch W; Staun M; Tandon RK; Altorjay I; Thillainayagam AV; Gratzer C; Nijhawan S; Thomsen LL
Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
[TBL] [Abstract][Full Text] [Related]
17. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron.
Lichtenstein GR; Onken JE
Dig Dis Sci; 2018 Nov; 63(11):3009-3019. PubMed ID: 30056562
[TBL] [Abstract][Full Text] [Related]
18. An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland.
Pollock RF; Muduma G
Clinicoecon Outcomes Res; 2021; 13():9-18. PubMed ID: 33442276
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
Stein J; Aksan A; Klemm W; Nip K; Weber-Mangal S; Dignass A
J Crohns Colitis; 2018 Jun; 12(7):826-834. PubMed ID: 29955835
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
